Physician profile
Charles Bruce
NPI 1740646421
$2,714.04
in general payments reported to CMS, 2019-2025
22 companies · $78.41 in 2025
The $78.41 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $716 · 2022: $501 · 2023: $780 · 2024: $639 · 2025: $78.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,496.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $601.06 | 2021-2025 | Xifaxan |
| Abbvie INC. | $352.35 | 2021-2024 | |
| Novo Nordisk INC | $328.71 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $306.22 | 2021-2024 | |
| Glaxosmithkline, LLC. | $191.34 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Tris Pharma INC | $154.03 | 2023-2024 | Dyanavel Xr |
| Lilly USA, LLC | $114.84 | 2021-2024 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $93.36 | 2021-2024 | Farxiga, Airsupra |
| Biohaven Pharmaceutical Holding Company LTD. | $75.21 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.28 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $53.15 | 2023-2024 | |
| Amgen INC. | $52.41 | 2022-2023 | Evenity, Prolia |
| Novartis Pharmaceuticals Corporation | $51.96 | 2023 | |
| Abbott Laboratories | $47.19 | 2023-2024 | Freestyle Libre 2 |
| Exact Sciences Corporation | $43.08 | 2023-2025 | Cologuard Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $38.48 | 2021 | |
| Janssen Pharmaceuticals, INC | $36.06 | 2021 | |
| Ibsa Pharma INC. | $33.70 | 2022-2023 | Tirosint, Licart |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.58 | 2021-2024 | Ofev |
| Medtronic, INC. | $17.90 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.95 | 2024 | Voquezna |
| Paratek Pharmaceuticals, INC. | $14.18 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Bruce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.